DE69011130D1 - Pharmazeutische zusammensetzung bestimmt zur behandlung oder vorbeugung von retroviralen infektionen. - Google Patents

Pharmazeutische zusammensetzung bestimmt zur behandlung oder vorbeugung von retroviralen infektionen.

Info

Publication number
DE69011130D1
DE69011130D1 DE69011130T DE69011130T DE69011130D1 DE 69011130 D1 DE69011130 D1 DE 69011130D1 DE 69011130 T DE69011130 T DE 69011130T DE 69011130 T DE69011130 T DE 69011130T DE 69011130 D1 DE69011130 D1 DE 69011130D1
Authority
DE
Germany
Prior art keywords
pharmaceutical composition
prevention
treatment
composition intended
retroviral infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69011130T
Other languages
English (en)
Other versions
DE69011130T2 (de
Inventor
Bruno Guy
Jean-Pierre Lecocq
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9013102A external-priority patent/FR2668065B1/fr
Application filed by Transgene SA filed Critical Transgene SA
Publication of DE69011130D1 publication Critical patent/DE69011130D1/de
Application granted granted Critical
Publication of DE69011130T2 publication Critical patent/DE69011130T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69011130T 1989-12-18 1990-12-18 Pharmazeutische zusammensetzung bestimmt zur behandlung oder vorbeugung von retroviralen infektionen. Expired - Fee Related DE69011130T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR8916726 1989-12-18
FR9013102A FR2668065B1 (fr) 1990-10-23 1990-10-23 Composition pharmaceutique destinee au traitement et a la prevention des infections retrovirales.
PCT/FR1990/000921 WO1991008769A1 (fr) 1989-12-18 1990-12-18 Composition pharmaceutique destinee au traitement ou a la prevention des infections retrovirales

Publications (2)

Publication Number Publication Date
DE69011130D1 true DE69011130D1 (de) 1994-09-01
DE69011130T2 DE69011130T2 (de) 1995-03-16

Family

ID=26227737

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69011130T Expired - Fee Related DE69011130T2 (de) 1989-12-18 1990-12-18 Pharmazeutische zusammensetzung bestimmt zur behandlung oder vorbeugung von retroviralen infektionen.

Country Status (8)

Country Link
EP (1) EP0506769B1 (de)
JP (1) JPH05502868A (de)
AT (1) ATE109006T1 (de)
AU (2) AU644621B2 (de)
CA (1) CA2071972A1 (de)
DE (1) DE69011130T2 (de)
DK (1) DK0506769T3 (de)
WO (1) WO1991008769A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3604093A (en) * 1992-02-07 1993-09-03 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Use of 5,5'-dithio-bis(2-nitrobenzoic acid) for inhibition of HIV protease
US5888992A (en) * 1992-03-11 1999-03-30 Narhex Limited Polar substituted hydrocarbons
ATE253050T1 (de) 1992-03-11 2003-11-15 Narhex Ltd Aminderivate von oxo- und hydroxy- substituierten kohlenwasserstoffen
EP0633881B1 (de) * 1992-03-11 2003-10-29 Narhex Limited Aminderivate von oxo- und hydroxy- substituierten kohlenwasserstoffen
US6071895A (en) * 1992-03-11 2000-06-06 Narhex Limited Polar-substituted hydrocarbons
SK281127B6 (sk) * 1992-09-09 2000-12-11 Amgen Inc. Použitie inhibítora serínovej leukocytovej proteázy
FR2778851B1 (fr) * 1998-05-19 2002-07-26 Aetsrn Composition a base d'inhibiteurs de cysteine-proteases pour retarder la senescence, l'autodestruction et l'hemolyse des erythrocytes
WO2005011649A2 (en) * 2003-05-19 2005-02-10 Vanderbilt University Methods of treating severe acute respiratory syndrome virus infections
WO2006091610A2 (en) * 2005-02-23 2006-08-31 The Brigham And Women's Hospital, Inc. Inhibitors of enveloped virus infectivity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43397B (en) * 1985-01-16 1989-06-30 Inst Jozef Stefan Process for insulation of poultry eggs cystatine from egg-white
EP0269311A3 (de) * 1986-11-17 1990-06-06 Merck & Co. Inc. Methoden zur Behandlung von Knochenleiden mittels Verabreichung von Cystein-Proteinaseinhibitoren

Also Published As

Publication number Publication date
AU644621B2 (en) 1993-12-16
AU6975591A (en) 1991-07-18
JPH05502868A (ja) 1993-05-20
DK0506769T3 (da) 1994-11-28
EP0506769A1 (de) 1992-10-07
CA2071972A1 (fr) 1991-06-19
EP0506769B1 (de) 1994-07-27
WO1991008769A1 (fr) 1991-06-27
ATE109006T1 (de) 1994-08-15
DE69011130T2 (de) 1995-03-16

Similar Documents

Publication Publication Date Title
ES2145913T3 (es) Inhibidores de metaloproteasas.
DE69034148D1 (de) Kombinationstherapie zur Prophylaxe und/oder Behandlung von gutartiger prostatischer Hyperplasie
DE68919358T2 (de) Zusammensetzung zur behandlung der schizophrenie.
DE69116380T2 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
ATE179888T1 (de) Ophthalmische zubereitung zur behandlung oder prävention von trockenem auge und krankheiten, die dadurch verursacht werden, enthaltend 12- sulfodehydroabietsäure
DE69501419T2 (de) Pharmazeutische Zusammensetzung zur Behandlung von Osteoporose enthaltend Xanthohumol
ES2045182T3 (es) Substancias fisiologicamente activas, un proceso para la preparacion de las mismas y composiciones farmaceuticas que las contienen.
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
RU95111308A (ru) Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция
DE69011130D1 (de) Pharmazeutische zusammensetzung bestimmt zur behandlung oder vorbeugung von retroviralen infektionen.
DE69522702T2 (de) Eine lagerstabile wässrige lösung zur infusion die einen thrombininhibitor enthält
GB9930768D0 (en) Composition
DE69010523D1 (de) Kit oder Zusammensetzung zur Vorbeugung oder Behandlung von HIV-1 Infektionen.
ATE5796T1 (de) Pharmazeutische zusammensetzung mit gehalt an l- alpha-methyl-3,4-dihydroxyphenylalanin und salicylamid zur behandlung hohen blutdrucks.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee